BRIEF-Xortx Announces 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Price Deficiency
Reuters · 05/24 11:17
XORTX Therapeutics' Xorlo eligible for accelerated approval, confirms FDA
Seeking Alpha · 05/04 14:04
BRIEF-FDA Confirms Eligibility Of XORLO For Accelerated Approval
Reuters · 05/04 11:13
BRIEF-Xortx Announces Receipt Of FDA Orphan Drug Tag To Treat Kidney Disease
Reuters · 04/21 11:25
Xortx stock climbs on FDA orphan drug status for kidney disease therapy
Seeking Alpha · 04/21 11:25
XORTX Therapeutics Inc. Gets FDA Orphan Drug Designation For Oxypurinol For Treatment Of Autosomal Dominant Polycystic Kidney Disease
Benzinga · 04/20 15:48
BRIEF-Xortx Therapeutics Inc- Announce Submission Of A Type D Meeting Request To Us FDA And A Response Setting Date For A Virtual Meeting On May 1, 2023
Reuters · 03/14 11:17
Xortx Announced Type D Meeting With FDA To Be Held May 1, 2023
Benzinga · 03/14 11:07
Xortx stock rises on FDA filing for orphan drug status for kidney disease therapy
Seeking Alpha · 02/01 13:22
BRIEF-XORTX Announces Submission Of Orphan Drug Designation Request For XRx-008 Program
Reuters · 02/01 12:21
XORTX Announced Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease
Benzinga · 02/01 12:05
BRIEF-XORTX Therapeutics Files For Mixed Shelf Of Up To $50 Mln
Reuters · 01/27 12:01
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga · 01/20 18:24
Dow Drops 150 Points; Crude Oil Up 1%
Benzinga · 01/19 19:54
XRTX Leaps after Good News from Kidney Treatment Study
TipRanks · 01/19 19:20
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 01/19 18:33
Nasdaq Down Over 100 Points; Procter & Gamble Posts In-Line Earnings
Benzinga · 01/19 17:00
Why Is Xortx Therapeutics (XRTX) Stock Up 30% Today?
Investor Place · 01/19 16:37
Xortx stock surges ~60% as potential kidney disease drug shows promise in early stage study
Seeking Alpha · 01/19 13:16
XORTX Shares Jump After Encouraging Data From Pharmacokinetics Study Of Formulated Oral Oxypurinol
Benzinga · 01/19 13:15
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan (rare) disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) associated with coronavirus infection. Its three lead product candidates are XRx-008, for the treatment of ADPKD; XRx-101, to treat AKI associated with Coronavirus / COVID-19 infection, AKI and associated health consequences. In addition, XRx-225 is a pre-clinical stage program for type 2 diabetic nephropathy. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company is evaluating xanthine oxidase inhibitor candidates for the XRx-225 program to treat T2DN.